Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2024 Jul 25;19(7):e0307574. doi: 10.1371/journal.pone.0307574

An exploration of the journey to diagnosis of Ehlers-Danlos Syndrome (EDS) for women living in Australia

Rachel Trudgian 1, Terri Flood 2,*
Editor: Martin E Matsumura3
PMCID: PMC11271888  PMID: 39052631

Abstract

Introduction

Ehlers-Danlos syndromes (EDS) is an umbrella term for a group of hereditary connective tissue disorders usually featuring hyperextensible skin, easy bruising, poor healing, and joint hypermobility. According to international Ehlers-Danlos support groups, the average time to diagnosis of this rare genetic condition is 10–12 years. Consequently, the journey to diagnosis can potentially be traumatic. This pilot study aims to explore female patients’ journey to a diagnosis of EDS while living in Australia.

Materials and methods

Over six weeks, from January to February 2023, a survey was distributed on EDS social media platforms including Facebook and LinkedIn. Ethical approval was obtained through the Ulster University Institute of Nursing and Health Research Ethics Filter Committee (FCNUR). Thematic and statistical analysis of the anonymous data was completed during March 2023.

Results

152 women completed the survey. More than half of the respondents first noticed symptoms of EDS more than 15 years prior to diagnosis and more than three quarters of respondents received other diagnoses prior to their EDS diagnosis. Most respondents saw their general practitioner, a physiotherapist and/or a rheumatologist prior to being correctly diagnosed with the condition. While some respondents had positive experiences with these health professionals, many felt that they were not listened to and, after doing their own research, had to educate their health professional/s about EDS.

Conclusion

This pilot survey demonstrated that the journey to diagnosis of EDS for women in Australia is frequently long and traumatic. Participants indicated that more EDS education and training is needed for health professionals, especially GPs, to improve the diagnostic process.

Implications for practice

Participants called for their self-reported symptoms to be listened to by health professionals and to be met with empathy and an open mind instead of being dismissed. Additional education and training to health professionals about connective tissue disorders including EDS may aid earlier diagnosis in Australia.

Introduction

Ehlers-Danlos syndromes (EDS) are a group of rare heritable connective tissue disorders [1], characterised ‘by the abnormal formation and/or assembly of collagen, fibrillin and elastin in the body’ (page 1) [2]. EDS can lead to multi-systemic complications including generalised joint hypermobility, joint instability complications, widespread musculoskeletal pain, poor skin integrity, cardiovascular dysfunction, and gastrointestinal dysfunction [2]. There is no cure for EDS [1,3], only symptom management and prevention of further deterioration [4]. While historically the prevalence of EDS was thought to be approximately 1 in 5000 cases annually worldwide, more recent figures suggest that prevalence is higher at around 120 per 100,000 [5].

Based on the 2017 international classification system, EDS is divided into 13 subtypes [1,6,7] of which Hypermobile EDS (hEDS) is the most common type [8,9], estimated to account for approximately 90% of EDS diagnoses [10]. hEDS is generally considered to be the least severe type of EDS but can lead to significant musculoskeletal complications resulting from hypermobility and joint instability, along with other comorbid conditions [10,11]. While skin hyperextensibility is seen in many types of EDS, this symptom is less common in hEDS [10]. Symptom severity and progression of hEDS is likely impacted by factors such as age, gender and lifestyle [7]. While most types of EDS are caused by mutations in genes, no gene has yet been identified as the cause of hEDS [1]. Consequently, a genetic diagnosis is indicated for all subtypes, except hEDS [10].

Past challenges in diagnosing hEDS have included poor knowledge of medical professionals due to its rarity [1216], its multisystem nature [10,17,18] and the lack of consistent diagnostic criteria for hEDS [16]. New criteria was developed in 2017 by the EDS International Consortium, to provide consistent diagnostic criteria with the aim of reducing future misdiagnoses [10]. Despite this change in diagnostic criteria, recent studies by Halverson et al. (2021) [13] and Wang et al. (2024) [14] have reported that the average time to diagnosis of hypermobility spectrum disorders (HSD), including Ehlers-Danlos syndrome, to be 11–16 years. Participants consistently report being referred to numerous specialists and obtaining multiple alternative diagnoses prior to their formal hEDS diagnosis [1214,19]. As a result, many hypermobile individuals are not correctly diagnosed until much later in life when joint damage may be irreversible [12]. Misdiagnoses can lead to inappropriate and sometimes dangerous treatment of their presenting symptoms [20], potentially resulting in an altered sense of self [21]. Earlier diagnosis is vital to ensure appropriate treatment and prevent future complications [22]. Obtaining a diagnosis of hEDS often then opens doors for obtaining additional, accurate diagnoses of postural orthostatic tachycardia Syndrome (POTS) and mast cell activation syndrome (MCAS) [23]. This is important as patients are increasingly presenting with this triad of syndromes together [9]. Recent studies which have assessed the lived experience of people through their diagnosis of EDS, have included experiences from the United Kingdom, Sweden and Belgium [12] and the United States of America [1214]. The lived experiences of people receiving a diagnosis of EDS in Australia is largely unreported. Given that Australia’s healthcare system was independently ranked 5th in the world in 2022, above all of these countries [24], it is important to gain an understanding of the EDS diagnostic experience to add to the global evidence of this rare disease.

Several reports indicate that hEDS occurs predominantly in females with over 90% of confirmed cases of hEDS being female [5,9,25]. Recent studies indicate that women with hEDS symptoms have a reduced quality of life and experience more severe sexual dysfunction (often linked to pelvic organ prolapse) compared to men [26]. Additionally, suicide risk is high in hEDS, with women reporting higher rates of suicide attempts compared to men [26]. Baeza-Velasco et al.’s 2022 study of women with hEDS reported that 31.4% of the sample had made at least one suicide attempt with 42.8% of patients assessed indicating some risk of suicide [27]. Given that the average time to diagnosis of hEDS is 10–16 years [1214] it is essential that information is collated from women who have been through this process to truly understand their lived experiences. Further, due to the lack of a pathognomonic biomarker for hEDS, patient reports of their symptoms, particularly before they are accurately diagnosed with hEDS, are often dismissed [1214,28]. Patients are sometimes referred for psychiatric evaluation, often told it is ‘all in their head’ and not real and classified as ‘somatisers’ [1214,29]. A recent Gender Pain Gap Index report [30] in the UK indicated that dismissal of physical symptoms most frequently occurs to women. For the same pain symptoms, only 44% of women surveyed received a diagnosis for their pain compared to 66% of men within 11 months [30]. Thirty percent of women felt that their time to diagnosis was negatively impacted because of their health professional dismissing their pain compared to 18% of men [30].

The primary aim of this study was to capture female patients’ perspectives and experience regarding their journey to diagnosis of EDS while living in Australia. Factors explored which may influence time to diagnosis included having other family members with an EDS diagnosis, types of health professionals visited and diagnostic tests used. Understanding factors which can impact time to an EDS diagnosis can help to highlight changes needed to the EDS diagnostic pathway and/or support services required for this rare condition in Australia.

Materials and methods

Study design

A pilot study was deemed appropriate as the first step to provide initial impressions of the diagnostic experience and potential interventions to help design future experimental research in this topic area [31].

A survey was chosen as the data collection method as it allows for data to be collected from a large, targeted population [32]. Given the large geographical distance between cities in Australia, a survey was deemed the most appropriate method. JISC Online Survey (formerly Bristol Online Survey—BOS) was utilised to distribute the survey anonymously and was supplied free of charge as part of a departmental contract with Ulster University. Due to fluctuating COVID restrictions at the time, and considering that many participants may be immunocompromised, an online survey had the advantage of enabling participants to complete the survey in the comfort of their own homes. Participants were also able to opt out of answering any question if they wished. A combination of open and closed response questions were chosen to allow flexibility and depth of responses. JISC enabled respondents to save their place in the survey and return at another time, provided it was within the six-week period. This was important, particularly given the levels of fatigue and pain respondents may have experienced while accessing an online survey, secondary to their EDS. Initial question design was based on an extensive literature search and the lead researcher’s anecdotal experience as an occupational therapist. Content validity was increased through discussions between the two researchers and following discussions with women with EDS living in Brisbane, Australia [33]. These discussions resulted in some minor modifications to the questionnaire; this was primarily related to ensuring the use of inclusive language throughout the survey. Questions were arranged in a logical order collecting demographic information in the earlier questions of the survey and then asking about participants’ experiences before, during and after they received their diagnosis of EDS. See survey in supplemental information. See Supporting information for full survey.

Participant recruitment

People were eligible to participate in this study if they identified as female, were over the age of eighteen, and had been living in Australia for more than one year before obtaining their diagnosis of EDS in Australia.

Participants were recruited by convenience sampling via social media (Facebook and LinkedIn). A review of all open and accessible Facebook pages relevant to the EDS community in Australia was conducted. Eleven Facebook pages were identified. Due to rules of the individual pages (no surveys allowed; only individuals with EDS were allowed to join), seven pages accepted the survey link to be shared. Of those seven pages, membership totalled 8,200, though there would likely have been crossover between the different pages as members are free to join as many pages as they wish. The survey was advertised by the lead author on the day the survey opened, 3rd January 2023, then reminders were posted at 2-week intervals and on the second last day before the survey closed on 15th February 2023.

Consent and ethics

Ethical approval for this study was obtained through the Nursing and Health Research Ethics Filter Committee in Ulster University in September 2022. The approval number for this study is FCNUR-22-062-A. The lead author conducted this research as part of an MSc through Ulster University, while practicing as an occupational therapist in Brisbane, Australia.

A brief cover letter accompanying the link to the survey outlined the inclusion criteria and the closing date of the survey. Participants were encouraged to click on the survey link and advised that the survey could take up to 20 minutes to complete. The first page of the survey outlined the purpose of the survey and invited participants who met eligibility criteria to continue. Participants had to indicate that they met each of the eligibility criteria to continue into the survey. It was clearly stated that the survey was anonymous and that participation in the survey implied consent by virtue of survey completion [34]. Participants were also informed, prior to starting the survey that the survey discussed potentially sensitive topics, which may cause some distress and subsequently that they may withdraw at any point until their survey is submitted.

Once the survey had been live for six weeks, it automatically closed and participants were no longer able to access the survey. The lead author posted a statement of thanks on the seven Facebook pages and LinkedIn page to the women who completed the survey.

Sample and sampling

Globally, as previously highlighted, EDS is thought to occur in approximately 120 per 100,000 people [35,36]. Based on this figure, and Australia’s population of over 26 million [37], there are approximately thirty-one thousand people living with various types of EDS in Australia, the majority of which are female [5,9,25]. An acceptable margin of error used in survey research is 5–10%, with a confidence level of 95% and a 50% response distribution [38]. Using the Raosoft sample size calculator [39], it was, therefore, determined that between 96 and 380 participants would need to be successfully recruited in order to yield statistically significant results.

Data analysis

Descriptive statistics were used to analyse data for single categorical variables and included frequencies and percentages. Cross tabulation was conducted to quantitatively analyse the relationship between variables including time to diagnosis, time of diagnosis and family history of EDS.

Qualitative analysis of the data was conducted using inductive thematic analysis as described by Williams and Moser [40]. Inductive analysis involves deriving meaning from the data without preconceptions [40]. Participants’ qualitative responses were captured through JISC and exported into an excel spreadsheet for coding. The first stage of coding included open coding; this involved read and re-reading of the responses to increase familiarity and understanding of the data [40]. During this stage sequences of words or phrases were manually coded in an iterative process. Unlike full interviews or focus groups, the volume of data was relatively low and therefore specialist software for aiding data analysis was not deemed necessary. Code notes were produced to explain the content of each of the codes. Axial coding was the second stage of coding in this analysis and involved development of the codes into categories and themes by identifying relationships between open codes [40]. This process was dynamic, requiring consideration of possible influencers relative to the findings.

Both study researchers independently completed the open coding and axial coding stages of this process. To improve inter-rater reliability, the researchers shared their code notes with each other [41] and discussed any discrepancies between the coding. Through reflection, reflexivity and discussion in a non-linear process, both researchers agreed on all final codes, categories and themes, exceeding suggested inter-rater reliability of 80% agreement between coders on 95% of the codes. This process of independent coding addresses the issue of objectivity and increases the rigour of the data analysis process [42].

Results

One hundred and fifty two eligible participants completed this survey regarding their journey to a diagnosis of EDS in Australia.

Demographic information

More than half (n = 79; 52%) of participants indicated that they lived in Queensland. The majority of participants identified that they were between 25 and 44 years old (n = 83; 54.6%) with 46 participants (30.3%) indicating that they were 45 years or older.

Participants most frequently identified that their highest level of education was completion of an undergraduate degree at university (n = 48; 31.6%), while 36 respondents (23.7%) had completed postgraduate studies. Sixty-five participants (32.8%) reported that they were working either full-time, part-time or on a casual basis. Some participants indicated that they were currently studying (n = 17; 11.2%). Fifteen (9.9%) respondents indicated that they are unemployed while 37 (24.3%) participants indicated that they are currently receiving the Disability Support Pension. See Table 1 for full demographic information.

Table 1. Demographic information of participants.

State of residence n (%)
Queensland 79 52.0
Victoria 37 24.3
New South Wales 24 15.8
South Australia 4 2.6
Western Australia 4 2.6
Tasmania 3 2.0
ACT 1 0.7
Northern Territory 0 0.0
Age range n (%)
18–24 23 15.1
25–34 40 26.3
35–44 43 28.3
45–54 31 20.4
55–64 12 7.9
65+ 3 2.0
Educational level n (%)
Undergraduate degrees 48 31.6
TAFE/college 47 30.9
Postgraduate studies 36 23.7
Finished high school (Year 12) 25 16.4
Finished school before Year 12 12 7.9
Employment Status n (%)
Working full-time 24 15.8
Working part-time 28 18.4
Working casually 13 8.6
Homemaker 15 9.9
Retired 6 3.9
Studying 17 11.2
Business owner 11 7.2
Unemployed 15 9.9
Receiving DSP 37 24.3
Other 27 17.8

Note: Participants were able to select more than one option for Educational level and Employment Status.

Types of EDS

There are thirteen subtypes of EDS, of which hypermobile EDS (hEDS) is the most common [35]. The majority of participants (n = 137; 90.1%) identified as having Hypermobile EDS (hEDS) which is consistent with previous research [1,43]. See Table 2 for full details.

Table 2. Types of EDS.

Type of EDS n (%)
Hypermobile EDS (hEDS) 137 90.1
Unknown 6 3.9
Classical EDS 3 2.0
Classical-like EDS 3 2.0
Vascular EDS (vEDS) 2 1.3
Cardiac-valvular EDS (cvEDS) 1 0.7

Forty-three respondents (28.3%) had a family member who had been diagnosed with EDS in Australia while 109 respondents (71.7%) were the only members of their family diagnosed with EDS. Of the 43 respondents who had a family member diagnosed with EDS, 32.6% indicated that this was their daughter. See Table 3 for full details.

Table 3. Family members diagnosed with EDS.

N (%)
Participants who did not have a family member diagnosed with EDS 109 71.7
Participants with family member diagnosed with EDS 43 28.3
Family member diagnosed with EDS;
 • Daughter 14 32.6
 • Sister 9 20.9
 • Son 9 20.9
 • Mother 8 18.6
 • Brother 1 2.3
 • Grandmother 1 2.3
 • Father 1 2.3

Cross tabulation revealed that, despite 43 respondents having a family member diagnosed with EDS, 32 of these respondents (74.4%) had symptoms for more than 15 years prior to obtaining an EDS diagnosis.

Thirty-seven participants (86%) who had a relative with an EDS diagnosis, took 10 years or greater to be diagnosed with EDS compared to 78 (71.6%) of those who did not have a relative with a diagnosis. See Table 4.

Table 4. Participants indicate how long they had symptoms prior to obtaining their official diagnosis (Cross tabulation of question 5 and question 7).

How long prior to obtaining your official diagnosis had you noticed symptoms? Do you have a family member who has been diagnosed with EDS in Australia? Totals
Yes No
Less than 1 year 2 2 4
1–2 years 1 6 7
3–4 years 1 13 14
5–9 years 2 10 12
10–14 years 5 14 19
More than 15 years ago 32 64 96
No answer 0 0 0
Totals 43 109 152

Prior to diagnosis of EDS

The majority of participants (n = 96; 63.2%) had been diagnosed with EDS since 2020. Fifty-three participants (34.9%) were diagnosed between 2010 and 2019. Ninety-six participants (63.2%) first noticed symptoms of EDS more than 15 years prior to their diagnosis. Prior to receiving their confirmed diagnosis of EDS, most patients saw their general practitioner (n = 144, 94.7%), a physiotherapist (n = 131, 86.2%) and/or a rheumatologist (n = 101; 66.4%). Other specialists consulted before being formally diagnosed with EDS included gastroenterologists, orthopaedic surgeons, gynaecologists, pain specialists, and neurologists/neurosurgeons. Other allied health professionals who were consulted included osteopaths, psychologists and occupational therapists.

The majority of participants (n = 129; 84.9%) indicated that they received alternative diagnoses prior to their formal EDS diagnosis. Most participants reported being diagnosed with anxiety and/or depression (n = 91; 73.4%) or another psychological condition (n = 47; 37.9%), chronic pain (n = 67; 54%), myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) (n = 58; 46.8%), or another physical condition including fibromyalgia (n = 18; 17.7%). Over 10% of respondents (n = 14) reported receiving more than nine diagnoses before being diagnosed with EDS. See Table 5 for further details.

Table 5. Experience prior to a diagnosis of EDS.

Obtained diagnosis of EDS n (%)
2020–present 96 63.2
2010–2019 53 34.9
2000–2009 2 1.3
Before 2000 1 0.7
Noticed symptoms of EDS before official diagnosis n (%)
Less than 1 year 4 2.6
1–2 years 7 4.6
3–4 years 14 9.2
5–9 years 12 7.9
10–14 years 19 12.5
More than 15 years 96 63.2
Professional consulted before formal diagnosis n (%)
General practitioner 144 94.7
Physiotherapist 131 86.2
Rheumatologist 101 66.4
Other 71 46.7
Cardiologist 60 39.5
Immunologist 29 19.1
Were you misdiagnosed prior to your diagnosis of EDS? N (%)
Misdiagnosed 129 84.9
Correctly diagnosed 23 15.1
Number of misdiagnoses n (%)
1–3 73 56.6
4–6 36 27.9
7–9 6 4.7
More than 9 14 10.9
Misdiagnosis * n (%)
Anxiety and/or depression 91 73.4
Chronic pain 67 54.0
Other physical 58 46.8
Generalised joint laxity 52 41.9
Other psychological 47 37.9
Chronic fatigue syndrome (CFS) 45 36.3
Dysautonomia 18 14.5
Fibromyalgia 18 17.7
Myalgic encephalomyelitis (ME) 13 10.5
Rheumatoid/Osteo/other arthritis 6 5.9
Marfan syndrome 4 3.2

* Participants could select more than one misdiagnosis.

Cross tabulation revealed that 72 out of the 96 participants (75%) who were most recently diagnosed in the period from 2020 to present, had symptoms of EDS for over 15 years before their official diagnoses. See Table 6.

Table 6. Participants indicate how long they had symptoms prior to obtaining their official diagnosis (Cross tabulation of question 6 and question 7).

Time period of diagnosis Length of time in years to diagnosis of EDS
<1 1–2 3–4 5–9 10–14 >15 Total
2020-present 3 2 6 4 9 72 96
2010–2019 1 5 7 7 10 23 53
2000–2009 0 0 1 1 0 0 2
Before 2000 0 0 0 0 0 1 1
4 7 14 12 19 96 152

After believing they had been misdiagnosed

From the 129 participants who indicated that they believed that they had received a misdiagnosis, 125 (96.9%) responded with comments to the question asking how they felt after being misdiagnosed. All of these participants identified that they felt negative emotions with some participants expressing more than one negative emotion. These emotions were stratified into two themes; 1) Feelings towards the Health Professional involved and 2) Internal feelings. The most common emotions expressed regarding the health professionals involved in their care included feeling frustrated/angry/annoyed (n = 50; 40%), ignored/dismissed/not taken seriously (n = 30; 24%) and patronised (treated like a hypochondriac) (n = 26; 20.8%). The most common internal emotions described included feelings of hopeless (n = 25; 20%), and feeling sad/depressed (n = 17; 13.6%) after being misdiagnosed. See Table 7 for further coding information.

Table 7. How participants felt after being misdiagnosed.

Feeling after being misdiagnosed n (%)
Theme 1: Feelings towards the health professional
Codes:
Frustrated/agitated/annoyed/angry 50 40.0
Ignored/invisible/dismissed/not listened to or taken seriously/not seen/disempowered 30 24.0
Not believed/told ‘all in my head’/treated like a hypochondriac/like I was going crazy 26 20.8
Didn’t agree with health professionals diagnosis/knew there was something more to symptoms 10 8.0
Misunderstood/hurt/let down 6 4.8
Theme 2: Internal feelings
Codes:
Hopeless/devastated/defeated/despairing/disheartened 25 20.0
Upset/sad/tearful/depressed 17 13.6
Confused 12 9.6
Judged 10 8.0
Lonely/abandoned/isolated/marginalised/that no one cared 5 4.0
Scared/anxious 3 2.4
Overwhelmed/stuck/didn’t know what to do/feel 3 2.4
Terrible/horrible 2 1.6
Like a failure/weak 2 1.6
Vulnerable 1 0.8
Suicidal 1 0.8

Note: Participants frequently talked about more than one emotion.

Participants explain their feelings:

‘Frustrated. I knew there was something more to my symptoms.’ (Participant 1) ‘Hurt, not seen, mistreated, angry, confused, lonely, depressed.’ (Participant 3) ‘Felt no hope. Told it was all ‘in my head’ a lot.’

(Participant 9)

‘Gaslit–like I was being dramatic, lazy, less than, making me question my identity and my experiences (especially being misdiagnosed as having trauma and I’d repressed it).’

(Participant 50)

Recurring themes when participants had negative experiences with health professionals included not being listened to/believed, being dismissed, or made to feel ‘stupid’; that their symptoms were all in their head.

One hundred and fourteen participants (75%) sought self-diagnosis online with 104 of these participants (91.2%) identifying that the information available online was helpful. Of the 104 participants who found online information helpful, the resources most valued were websites (n = 88; 84.6%), Facebook support groups (n = 78; 75%) and medical journal articles (n = 76; 73.1%). See Table 8 for further information.

Table 8. Actions of participants after misdiagnosis.

Action after receiving a misdiagnosis n (%)
Sought self-diagnosis online 114 75.5
Did not seek self-diagnosis online 37 24.5
Was the online information helpful? n (%)
Yes 104 91.2
No 10 8.8
Helpful media sources * n (%)
Websites 88 84.6
Facebook support groups 78 75.0
Medical journal articles 76 73.1
YouTube lectures/videos 37 35.6
Podcasts 15 14.4
Others 13 12.5

* Participants could select more than one media source.

Formal diagnostic process

Ultimately, 54.6% of respondents were formally diagnosed by a rheumatologist (n = 83), 29.6% by a geneticist (n = 45), 8.5% by a GP (n = 13) and 6.6% by a physiotherapist (n = 10).

During the diagnostic process, most participants were assessed using the Beighton scale (n = 136; 89.5%), self-report of pain/other symptoms scales (n = 117; 77%), clinical criteria (n = 116; 76.3%), the international diagnostic checklist for hEDS (n = 93; 61.2%) and tools to assess the presence of other potentially associated disorders (n = 88; 57.9%). See Table 9 for further information.

Table 9. Formal diagnostic process.

Health Professional responsible for diagnosis of EDS* n (%)
Rheumatologist 83 54.6
Geneticist 45 29.6
General Practitioner (GP) 13 8.5
Other 12 7.9
Physiotherapist 10 6.6
Cardiologist 4 2.6
Sports Physician 2 1.3
Diagnostic tools used n (%)
Beighton scale 136 89.5
Self-report of pain/other symptoms scales 117 77.0
Clinical criteria 116 76.3
International diagnostic checklist for hEDS 93 61.2
Tools to assess the presence of other potentially associated disorders 88 57.9
Other 29 19.1
Don’t know 6 3.9

* Some participants indicated that more than one health professional diagnosed their EDS.

* Some participants indicated more than one diagnostic tool.

One hundred and forty six of the 152 respondents (96.1%) included comments about how they felt during the diagnostic process. Participants reported a variety of emotions during this process that were also stratified into two themes; 1) Feelings towards the Health Professional involved and 2) Internal feelings. During the diagnostic process, they most commonly felt validated/relieved that they were being listened to by a healthcare professional (n = 70; 47.9%) but a large number of participants reported feeling stressed/anxious/overwhelmed about their diagnosis and what that might mean for their future (n = 66; 45.2%). See Table 10 for full details.

Table 10. How participants felt during the diagnostic process.

Feelings during and after the Diagnostic process n (%)
Theme 1: Feelings towards the health professional
Codes:
Relieved that a health professional was listening 70 47.9
Like the specialist didn’t know enough 2 1.3
Theme 2: Internal Emotions
Codes:
Nervous/anxious/fearful/worried/distressed/concerned about diagnosis 66 45.2
Tired/exhausted 8 5.5
Annoyed/frustrated 7 4.8
Shocked/bemused/confused 6 4.1
Felt that my body had failed me 2 1.4
Alienated/alone 2 1.4
Curious 2 1.4
Less confused 1 0.7
Determined 1 0.7

Note: Participants frequently talked about more than one emotion.

Ninety-eight percent of participants reported that one or more health professionals treated them well during the diagnostic process with most respondents reporting feeling listened to and validated. Participants describe their feelings during and after their EDS diagnosis:

‘I was so overwhelmed that I cried. Not because of the actual diagnosis but because after all these years someone actually listened to me and cared.’

(Participant 16)

‘They believed me! It was so unusual and unexpected that I cried with gratitude and relief.’ (Participant 28)

‘They believed me and didn’t think I was exaggerating my symptoms or health issues and weren’t dismissive.’

(Participant 17)

‘Happy to have a name for something and a reason behind all my pain, but worried that this isn’t something that can be cured, and my life is now forever changed.’

(Participant 4)

‘Relief and validation. Also, hopelessness and exhaustion for a period after; I realised I had invested all of my energy into working out and proving what was wrong.’

(Participant 30)

Looking to the future

One hundred and forty-five participants (95.4%) identified that they had to educate health professionals about EDS. This included 48 of the 145 participants (33.1%) feeling like they had to educate ‘most or all health professionals’ involved in their care. A further 64 participants reported educating their general practitioner (GP) (44.1) about their diagnosis. See Table 11 for further information.

Table 11. Participant’s views regarding educating health professionals about EDS.

Did you feel you had to educate health professionals about EDS? n (%)
Yes 145 95.4
No 7 4.6
If yes, which health professionals? * n (%)
General practitioner 64 44.1
Most health professionals 27 18.6
Physiotherapist 24 16.6
All health professionals 21 14.5
Emergency department doctors 13 9.0
Cardiologist 8 5.5
Nurses 7 4.8
Gastro specialists 6 4.1
Dentist 4 2.8
Neurosurgeon/Neurologist 4 2.8
Rheumatologist 3 2.1
Orthopaedic surgeon 3 2.1
Psychologist 3 2.1
Anaesthetist 2 1.4
Gynaecologist 2 1.4
Exercise physiologist 1 0.7
Spinal surgeon 1 0.7
Allergist 1 0.7
Respiratory physician 1 0.7
Osteopath 1 0.7
Endocrinologist 1 0.7
Pulmonologist 1 0.7
Dietitian 1 0.7
Occupational therapist 1 0.7

* Participants could choose more than one option.

One hundred and forty-six participants (96.1%) provided suggestions for what they thought might improve the diagnostic process for women with EDS living in Australia. Ninety-eight participants (67%) suggested more training, education, and greater awareness for health professionals. Nearly a third of these respondents (n = 42; 28.8%) suggested that, if health professionals listen to and believe their patients and avoid dismissing them, their journey to diagnosis would be better. See Table 12 for further information.

Table 12. Participants’ opinions regarding what might improve the journey to diagnosis of EDS for women living in Australia.

Suggestions to improve the journey to diagnosis of EDS* n (%)
Training/education/awareness for health professionals 98 67.1
Health professionals listen to and believe their patients/less dismissal 42 28.8
Increasing public awareness/reducing the stigma 15 10.3
One central service to go to/more EDS specialists 12 8.2
More support for doctors/better resources/more research 9 6.2
Open-minded health professionals/ HPs determined to find answers 4 2.7
Doctors to lose their egos and say they don’t know 4 2.7
Early diagnosis/screening 3 2.1
Educating medical students 3 2.1
Clear diagnostic pathway 3 2.1
An overall review of being dismissive of women’s experiences 2 1.4
Less judgement of patients 1 0.7
AHPRA to investigate patient complaints 1 0.7
Doctors who do what they say they will do 1 0.7

*Participants could choose more than one option.

One hundred and thirty-four respondents (88.2%) provided suggestions about how information might be better distributed to treating health professionals and/or the broader community to increase awareness of EDS. Some suggestions included more training specifically to doctors and medical students (n = 26; 19.4%) and ongoing training/information sessions available to any health professionals (n = 45; 33.6%), better awareness/campaigns, physical challenges (e.g. a fundraising walk/run), public media coverage (n = 22; 16.4%), more medical conferences (n = 12; 9%) and medical journal articles/research into EDS (n = 15; 11.2%). See Table 13 for further information.

Table 13. How might information be best disseminated to increase awareness of EDS?.

n (%)
Ongoing training/workshops/info sessions to any medical professional 45 33.6
Taught at med school/university 26 19.4
Awareness campaigns/events/media 23 17.2
Unsure 18 13.4
Medical journal articles including case presentations/real life patient stories/ research/funding into EDS 15 11.2
Medical conferences 12 9.0
Australian foundation 5 3.7
Fact sheets/easy-read flyers/diagnostic pathway 3 2.2
ECHO program 3 2.2
RACGPs 3 2.2
Representation on TV 3 2.2
Contact with advocates 3 2.2
EDS website 2 1.5
Patient led 1 0.7
Incentive to include EDS treatment in public hospital system 1 0.7
Places to go and learn more 1 0.7
TED talks 1 0.7
All specialists in one place 1 0.7
Information distribution 1 0.7
Through professional networks 1 0.7
Newsletters 1 0.7
Books 1 0.7
Add to curriculum in schools 1 0.7
Bulletins from Department of Health 1 0.7

*Participants could chose more than one option.

Discussion

This survey demonstrated that the majority of women with a diagnosis of EDS in Australia experience negative emotions, distress and trauma during their journey to diagnosis, consistent with findings from similar studies from other developed countries. Participants indicated that their journey to diagnosis was long, with the majority of participants in this study first noticing symptoms more than 15 years prior to an EDS diagnosis. This long journey to diagnosis is consistent with previous publications [13,14,17,18,43] and in fact is even longer than previous reports in this female-only study population. While the majority of participants in this study were diagnosed since 2020, most of them reported that they had been experiencing symptoms for 15 years prior to their official diagnosis. Interestingly, having a relative with a diagnosis of EDS, and therefore family history, did not reduce the time to diagnosis for the participants in this study.

These findings suggest that, similar to other countries [1214], there has been minimal, if any, increase in awareness of EDS in GPs and other health professionals in Australia in recent years. As GPs have an essential role in the coordination of referrals, especially in patients with complex chronic conditions [44], it is important that education for GPs is prioritised.

The International Diagnostic checklist (IDC) for hEDS, developed by the International Consortium 2017 [45,46], has been established to increase consistency in the diagnosis of hypermobile EDS (hEDS) [47,48], the type of EDS diagnosed in over 90% of the participants in this study. This checklist includes a Beighton score alongside two sets of assessment checklists, which include family history [10,35,43,49]. The presence of all three criteria indicates a clinical diagnosis of hEDS [10,35,43,49]. A GP toolkit is also available through Elhers Danlos Support UK to further guide GP referrals [50]. In this study, participants reported that diagnosing clinicians based their diagnosis of EDS most frequently on a variety of tools including the Beighton scale, clinical criteria and patient-reported pain scores, with only around sixty percent of them indicating that their diagnosis was based on the IDC. Additionally, despite family history being integrated into the IDC, participants with a family history of EDS were not diagnosed faster than those without a family history. However, it must also be acknowledged that patients are not experts in diagnostic testing and therefore the accuracy of this information may not be reliable and cannot be verified.

Most participants felt that they were misdiagnosed prior to receiving their formal diagnosis of EDS with over ten percent of respondents reporting that they received more than nine alternative diagnoses prior to their EDS diagnosis. While patients with hEDS frequently present with comorbidities like migraine headaches, postural orthostatic tachycardia syndrome (POTS) and fibromyalgia (FM) [19], the number of alternative diagnoses reported in this study is higher than those reported in similar studies [19,49,51,52]. In this study 18% of women reported being diagnosed with FM prior to their formal EDS diagnosis. However, as FM alone is not formally recognised by the National Disability Insurance Agency in Australia (NDIA) or Centrelink (Australian welfare system) [53], there is much debate about how helpful a diagnosis of FM is in terms of support and care for people living in Australia.

While some participants were diagnosed with other physical conditions prior to their EDS diagnosis, the majority were diagnosed with psychological conditions, with some participants describing feeling that health professionals perceived them as ‘crazy’, with symptoms being ‘all in their head’, or being hypochondriacs. Unfortunately, this finding is consistent with previous research findings [1214,15,29,54], resulting in an experience which can be dehumanising, causing psychological distress to patients [55] and increasing mistrust in the medical profession [56]. Feeling that they are receiving repeat misdiagnoses may also cause people with EDS to give an inaccurate report of their symptoms in an effort to be heard [57] or can cause them to disengage with health professionals, deterring them from presenting at a hospital for treatment [58,59].

Ehler Danlos Support UK suggest that key roles of the GP should be in diagnosing hEDS, validating the patient’s symptoms and co-ordinating care [50]. Therefore, these findings warrant further research to evaluate GP’s current knowledge of the IDC and how it is currently being utilised in practice in Australia. This may also reveal barriers to GP referrals which are currently unknown. In previous studies, GPs have cited important factors influencing the referral process as being their internal training, guidelines provided, access to specialists and confidence in the specialists [44]. Future research should focus on the impact of educating GPs to aid the referral process for suspected EDS, ultimately with the goal of diagnosing this condition earlier.

Many participants reported that they did not feel listened to by their GP and other health professionals and that these professionals were not well informed about EDS or the possibility that they might have EDS. Participants indicated that if health professionals were more open to patients’ suggestions, they may have felt more supported during the diagnostic process. This finding is consistent with previous research [1214,60,61] which also highlights the importance of including patients in open discussion and decision-making processes. Participants viewed it favourably when health professionals listened to them and did not dismiss their concerns. In a study by Bradshaw et al. [62], patients with chronic and complex care needs described being listened to as one of the most important aspects of building trust with their clinician. It is important that health professionals prioritise listening to their patients and contribute to validating their patients’ experiences. It is worth noting that most respondents conducted their own research into their symptomatology, usually online. This is consistent with Knight et al’s study [46] which reported that people with an EDS diagnosis are not only aware of current EDS research but also of the deficiencies within the EDS care pathway. This further highlights the lack of support in place for patients as they wait for a formal diagnosis of EDS.

Physiotherapy has a key role to play in the management of hypermobile EDS [63]. A 2011 survey by Rombaut et al. found that 63.4% of the hypermobile EDS patients enrolled in a physical therapy program reported a positive effect of the treatment. However, a recent study showed a lack of confidence by physiotherapists in assessment and management of hypermobile EDS [63]. Physiotherapists in this study were reported to be central to the diagnosis of EDS in 6.6% of cases, emphasising their potential role in identifying potential EDS cases and making appropriate referrals to confirm this diagnosis. Given the importance of their role in EDS rehabilitation in Australia, EDS education for physiotherapists should also be prioritised and integrated into undergraduate education as a mandated component of the curriculum. This education would include review of the components of the IDC alongside theoretical and practical learning regarding the appropriate treatment for patients with all types of EDS.

Despite a geneticist diagnosing almost a third of EDS cases in this study, there is currently no identifable gene which has been found to be associated with hEDS [46,47], the type of EDS diagnosed in the majority of patients [8,9]. Genetic testing is available for every type of EDS except for hEDS [8,9]. This suggests that, while geneticists have strong knowledge of all types of EDS, the services that they provide are mainly suitable for only a small number of EDS patients. Subsequently, referral pathways from GPs for people with suspected EDS need to be more clearly guided to ensure that resources are been utilised optimally.

Ultimately, participants in this study suggested that more education and training for all health professionals in Australia, as well as raising public awareness of EDS, may help to improve the diagnostic journey for individuals living with EDS in the future.

Limitations

As with the majority of studies, the design of the current study is subject to limitations.

One such limitation was the method of recruitment through convenience sampling. The survey was only offered and advertised online on two social media platforms. This prevented access for participants who might not be active online, not have access to smart technology or may not engage in social media. Due to self-selection, there may be differences between the people who choose to participate in the survey compared to those who choose not to participate [64]. Additionally, the survey was only open for six weeks which may not have given some participants adequate time to find out about the survey and/or complete it. The convenience sampling method used in the study is prone to biases that cannot be generalised beyond the specific sample studied [65]. As this study was a pilot study, the results are helpful in generating hypotheses for more rigorous research designs in the future.

While the survey content validity was increased through discussions between the two researchers and with women with EDS living in Brisbane, Australia [33], the questionnaire utilised in this study was not a validated measure and therefore its psychometric properties and its methodological quality have not been evaluated [66]. The wording of Question 9 regarding ‘misdiagnosis’ could be perceived as leading. Patients’ perceptions of being misdiagnosed, and their understanding of what diagnostic tool has been used, can be highly subjective and influenced by their understanding of their symptoms and conditions. The questionnaire does not include a mechanism for verifying the reported misdiagnoses against medical records or clinical evaluations. Without validation from healthcare professionals, it is impossible to determine if the reported misdiagnoses are accurate. While the lead researcher’s expertise is in managing EDS complications, including an expert in EDS diagnosis, such as a geneticist or rheumatologist, would have increased the questionnaire’s accuracy and relevance.

Some participants who were diagnosed some years ago may not recall details of their diagnosis accurately leading to risk of bias; this may either underestimate or overestimate the issues raised in the survey [67].

Focusing only on the lived experience of women in Australia is another limitation of this study. The lived experiences of all genders, including men, non-binary and gender fluid individuals, is under-researched.

In the future, it would be beneficial to recruit more broadly using a variety of communication methods to reach more individuals with EDS, include all genders, and delve deeper into the lived experiences of all people living with EDS in Australia and beyond.

Conclusion

Based on these findings, it is reasonable to propose that increased education of GPs and other key health professionals involved in EDS care, could improve the journey to diagnosis for women living in Australia. Increasing awareness in the general public as well as within the health and disability sectors may allow for quicker identification of EDS symptoms, reducing unnecessary patient stress and distress during the diagnostic process and lead to shorter lengths of time to diagnosis of this rare condition. This could mean better mental health and wellbeing for patients before, during and after their diagnosis, which may lead to better health outcomes as they adjust to living with EDS. Providing education and training to GPs and other health professionals will be challenging but may be essential to improve the lives of people with EDS in Australia.

Supporting information

S1 Appendix. Participant survey.

(DOCX)

pone.0307574.s001.docx (17.7KB, docx)

Acknowledgments

We would like to thank all of the people with EDS who participated in the design of this research study and also those who completed the survey.

Data Availability

Access to the full data can be obtained by request to the Nursing and Health Research Ethics Filter Committee in Ulster University (contact wg.kernohan@ulster.ac.uk).

Funding Statement

The author(s) received no specific funding for this work.

References

  • 1.Malfait F, Castori M, Francomano CA, Giunta C, Kosho T, Byers PH. The ehlers–danlos syndromes. Nature Reviews Disease Primers. 2020. Jul 30;6(1):64. Available at: https://www.pubmed.ncbi.nlm.nih.gov/32732924. doi: 10.1038/s41572-020-0194-9 [DOI] [PubMed] [Google Scholar]
  • 2.Mittal N, Mina DS, McGillis L, Weinrib A, Slepian PM, Rachinsky M, et al. The GoodHope Ehlers Danlos Syndrome Clinic: development and implementation of the first interdisciplinary program for multi-system issues in connective tissue disorders at the Toronto General Hospital. Orphanet Journal of Rare Diseases. 2021. Dec;16(1):1–9. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8353438/. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Rombaut L, Malfait F, De Wandele I, Taes Y, Thijs Y, De Paepe A, et al. Muscle mass, muscle strength, functional performance, and physical impairment in women with the hypermobility type of Ehlers-Danlos syndrome. Arthritis care & research. 2012. Oct;64(10):1584–92. doi: 10.1002/acr.21726 [DOI] [PubMed] [Google Scholar]
  • 4.Miller E, Grosel JM. A review of Ehlers-Danlos syndrome. Jaapa. 2020. Apr 1;33(4):23–8. Available at: https://journals.lww.com/jaapa/Fulltext/2020/04000/A_review_of_Ehlers_Danlos_syndrome.3.aspx. doi: 10.1097/01.JAA.0000657160.48246.91 [DOI] [PubMed] [Google Scholar]
  • 5.Demmler JC, Atkinson MD, Reinhold EJ, Choy E, Lyons RA, Brophy ST. Diagnosed prevalence of Ehlers-Danlos syndrome and hypermobility spectrum disorder in Wales, UK: a national electronic cohort study and case–control comparison. BMJ open. 2019. Nov 1;9(11):e031365. doi: 10.1136/bmjopen-2019-031365 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Miklovic, T., & Sieg, V. C. (2019). Ehlers danlos syndrome. [PubMed]
  • 7.Gensemer C, Burks R, Kautz S, Judge DP, Lavallee M, Norris RA. Hypermobile Ehlers-Danlos syndromes: Complex phenotypes, challenging diagnoses, and poorly understood causes. Developmental Dynamics. 2021. Mar;250(3):318–44. doi: 10.1002/dvdy.220 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.NHS. Ehlers-Danlos syndromes. https://www.nhs.uk/conditions/ehlers-danlos-syndromes/#:~:text=There%20are%2013%20types%20of,vascular%20EDS%20and%20kyphoscoliotic%20EDS Last accessed: 26/02/2024.
  • 9.Kohn A, Chang C. The relationship between hypermobile Ehlers-Danlos syndrome (hEDS), postural orthostatic tachycardia syndrome (POTS), and mast cell activation syndrome (MCAS). Clinical Reviews in Allergy & Immunology. 2020. Jun;58:273–97. [DOI] [PubMed] [Google Scholar]
  • 10.Tinkle B, Castori M, Berglund B, Cohen H, Grahame R, Kazkaz H, et al. Hypermobile Ehlers–Danlos syndrome (aka Ehlers–Danlos syndrome Type III and Ehlers–Danlos syndrome hypermobility type): Clinical description and natural history. InAmerican Journal of Medical Genetics Part C: Seminars in Medical Genetics 2017. Mar (Vol. 175, No. 1, pp. 48–69). [DOI] [PubMed] [Google Scholar]
  • 11.Malfait, Fransiska, Richard Wenstrup, and Anne De Paepe. "Classic ehlers-danlos syndrome." (2018).
  • 12.Bennett SE, Walsh N, Moss T, Palmer S. The lived experience of Joint Hypermobility and Ehlers-Danlos Syndromes: a systematic review and thematic synthesis. Physical Therapy Reviews. 2019. Mar 4;24(1–2):12–28. [Google Scholar]
  • 13.Halverson CM, Clayton EW, Garcia Sierra A, Francomano C. Patients with Ehlers–Danlos syndrome on the diagnostic odyssey: Rethinking complexity and difficulty as a hero’s journey. In American Journal of Medical Genetics Part C: Seminars in Medical Genetics 2021. Dec (Vol. 187, No. 4, pp. 416–424). Hoboken, USA: John Wiley & Sons, Inc. doi: 10.1002/ajmg.c.31935 [DOI] [PubMed] [Google Scholar]
  • 14.Wang YT, Jahani S, Morel-Swols D, Kapely A, Rosen A, Forghani I. Patient experiences of receiving a diagnosis of hypermobile Ehlers–Danlos syndrome. American Journal of Medical Genetics Part A. 2024. Mar 28:e63613. doi: 10.1002/ajmg.a.63613 [DOI] [PubMed] [Google Scholar]
  • 15.Berglund B, Anne-Cathrine M, Randers I. Dignity not fully upheld when seeking health care: experiences expressed by individuals suffering from Ehlers–Danlos syndrome. Disability and rehabilitation. 2010. Jan 1;32(1):1–7. doi: 10.3109/09638280903178407 [DOI] [PubMed] [Google Scholar]
  • 16.McGillis L, Mittal N, Santa Mina D, So J, Soowamber M, Weinrib A, et al. Utilization of the 2017 diagnostic criteria for hEDS by the Toronto GoodHope Ehlers–Danlos syndrome clinic: A retrospective review. American journal of medical genetics Part A. 2020. Mar;182(3):484–92. doi: 10.1002/ajmg.a.61459 [DOI] [PubMed] [Google Scholar]
  • 17.De Paepe A, Malfait F. The Ehlers–Danlos syndrome, a disorder with many faces. Clinical genetics. 2012. Jul;82(1):1–1. doi: 10.1111/j.1399-0004.2012.01858.x [DOI] [PubMed] [Google Scholar]
  • 18.Gazit Y, Jacob G, Grahame R. Ehlers–Danlos syndrome—hypermobility type: a much neglected multisystemic disorder. Rambam Maimonides Medical Journal. 2016. Oct;7(4). Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5101008/. doi: 10.5041/RMMJ.10261 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Halverson CM, Cao S, Perkins SM, Francomano CA. Comorbidity, misdiagnoses, and the diagnostic odyssey in patients with hypermobile Ehlers-Danlos Syndrome. Genetics in Medicine Open. 2023. Apr 28:100812. [Google Scholar]
  • 20.Aubry-Rozier B, Schwitzguebel A, Valerio F, Tanniger J, Paquier C, Berna C, et al. Are patients with hypermobile Ehlers–Danlos syndrome or hypermobility spectrum disorder so different?. Rheumatology international. 2021. Oct;41(10):1785–94. doi: 10.1007/s00296-021-04968-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Ishiguro H, Yagasaki H, Horiuchi Y. Ehlers-Danlos syndrome in the field of psychiatry: a review. Frontiers in Psychiatry. 2022. Jan 11;12:803898. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787077/. doi: 10.3389/fpsyt.2021.803898 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Terry RH, Palmer ST, Rimes KA, Clark CJ, Simmonds JV, Horwood JP. Living with joint hypermobility syndrome: patient experiences of diagnosis, referral and self-care. Family practice. 2015. Jun 1;32(3):354–8. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445137/. doi: 10.1093/fampra/cmv026 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Wang E, Ganti T, Vaou E, Hohler A. The relationship between mast cell activation syndrome, postural tachycardia syndrome, and Ehlers-Danlos syndrome. In Allergy & Asthma Proceedings 2021. May 1 (Vol. 42, No. 3). Available at: https://www.ingentaconnect.com/content/ocean/aap/2021/00000042/00000003/art00016. doi: 10.2500/aap.2021.42.210022 [DOI] [PubMed] [Google Scholar]
  • 24.World Index of Health Care Innovation (2023). Key Findings from the 2022 World Index of Healthcare Innovation. https://freopp.org/key-findings-from-the-2022-world-index-of-healthcare-innovation-e2a772f55b92.
  • 25.Ehlers Danlos News (2022). Lower Quality of Life Found in Young Women With Hypermobility. https://ehlersdanlosnews.com/news/orthostatic-intolerance-reduces-life-quality-young-women-hypermobility/.
  • 26.Bennett SE, Walsh N, Moss T, Palmer S. Understanding the psychosocial impact of joint hypermobility syndrome and Ehlers–Danlos syndrome hypermobility type: a qualitative interview study. Disability and rehabilitation. 2021. Mar 12;43(6):795–804. doi: 10.1080/09638288.2019.1641848 [DOI] [PubMed] [Google Scholar]
  • 27.Baeza-Velasco C, Hamonet C, Montalescot L, Courtet P. Suicidal behaviors in women with the hypermobile Ehlers–Danlos syndrome. Archives of suicide research. 2022. Jul 3;26(3):1314–26. doi: 10.1080/13811118.2021.1885538 [DOI] [PubMed] [Google Scholar]
  • 28.Sinibaldi L, Ursini G, Castori M. Psychopathological manifestations of joint hypermobility and joint hypermobility syndrome/Ehlers–Danlos syndrome, hypermobility type: The link between connective tissue and psychological distress revised. In American Journal of Medical Genetics Part C: Seminars in Medical Genetics 2015. Mar (Vol. 169, No. 1, pp. 97–106). doi: 10.1002/ajmg.c.31430 [DOI] [PubMed] [Google Scholar]
  • 29.Bulbena-Cabré A, Baeza-Velasco C, Rosado-Figuerola S, Bulbena A. Updates on the psychological and psychiatric aspects of the Ehlers–Danlos syndromes and hypermobility spectrum disorders. American Journal of Medical Genetics Part C: Seminars in Medical Genetics 2021. Dec (Vol. 187, No. 4, pp. 482–490). Hoboken, USA: John Wiley & Sons, Inc. doi: 10.1002/ajmg.c.31955 [DOI] [PubMed] [Google Scholar]
  • 30.Nurofen UK. Gender Pain Gap Index Report (November 2023). https://www.nurofen.co.uk/static/nurofen-gender-pain-gap-index-report-2023-94a5039e65c1051240cc359d8bc2787a.pdf Last accessed 24/02/2024.
  • 31.Tseng CH, Sim D. Sample size planning for pilot studies. arXiv preprint arXiv:2105.05483. 2021 May 12.
  • 32.Jones TL, Baxter MA, Khanduja V. A quick guide to survey research. The Annals of The Royal College of Surgeons of England. 2013. Jan;95(1):5–7. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3964639/. doi: 10.1308/003588413X13511609956372 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Tsang S, Royse CF, Terkawi AS. Guidelines for developing, translating, and validating a questionnaire in perioperative and pain medicine. Saudi journal of anaesthesia. 2017. May;11(Suppl 1):S80. doi: 10.4103/sja.SJA_203_17 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Buchanan E.A. and Hvizdak E.E. 2009. Online survey tools: ethical and methodological concerns of human research ethics committees. Journal of Empirical Research on Human Research Ethics. Jun 4(2), 37–48. Available at: https://pubmed.ncbi.nlm.nih.gov/19480590/. doi: 10.1525/jer.2009.4.2.37 [DOI] [PubMed] [Google Scholar]
  • 35.Ehlers-Danlos News. 2020. Prevalence of EDS. https://ehlersdanlosnews.com/prevalence-of-eds/ Last accessed 18/01/2024.
  • 36.The Ehlers-Danlos Society. 2023. What is EDS? https://www.ehlers-danlos.com/what-is-eds/ Last accessed 18/01/2024.
  • 37.Worldometer. 2023. Australia Population Live. https://www.worldometers.info/world-population/australia-population/ Last ccessed 18/01/2024.
  • 38.Suresh KP, Chandrashekara S. Sample size estimation and power analysis for clinical research studies. Journal of human reproductive sciences. 2012. Jan 1;5(1):7–1 doi: 10.4103/0974-1208.97779 [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  • 39.Raosoft. 2004. Sample size calculator. http://www.raosoft.com/samplesize.html Last accessed 24/02/2024.
  • 40.Williams M., and Moser T. 2019. The art of coding and thematic exploration in qualitative research. International Management Review, Jan 1;15(1):45–55. Available at: http://www.imrjournal.org/uploads/1/4/2/8/14286482/imr-v15n1art4.pdf. [Google Scholar]
  • 41.McAlister AM, Lee DM, Ehlert KM, Kajfez RL, Faber CJ, Kennedy MS. Qualitative coding: An approach to assess inter-rater reliability. In2017 ASEE annual conference & exposition 2017 Jun 24.
  • 42.Meyrick J. What is good qualitative research? A first step towards a comprehensive approach to judging rigour/quality. Journal of health psychology. 2006. Sep;11(5):799–808. doi: 10.1177/1359105306066643 [DOI] [PubMed] [Google Scholar]
  • 43.Ehlers-Danlos Support UK. 2017. EDS Diagnosis. https://www.ehlers-danlos.org/what-is-eds/information-on-eds/diagnosis/ Last accessed 18/01/2024.
  • 44.Tzartzas K, Oberhauser PN, Marion-Veyron R, Bourquin C, Senn N, Stiefel F. General practitioners referring patients to specialists in tertiary healthcare: a qualitative study. BMC family practice. 2019. Dec;20:1–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.The Ehlers-Danlos Society. 2024. hEDS Diagnostic Checklist. https://www.ehlers-danlos.com/heds-diagnostic-checklist/ Last accessed 26/02/2024.
  • 46.Knight DR, Confiado SM, Bruno KA, Fairweather D, Seymour-Sonnier AM, Jain A, et al. Establishing an Ehlers-Danlos syndrome clinic: lessons learned. SN Comprehensive Clinical Medicine. 2022. Jul 5;4(1):138. doi: 10.1007/s42399-022-01218-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Hakim A. Hypermobile Ehlers-Danlos Syndrome. 2004 Oct 22 [Updated 2024 Feb 22]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. https://www.ncbi.nlm.nih.gov/books/NBK1279/#:~:text=Hypermobile%20EDS%20is%20inherited%20in,chance%20of%20inheriting%20the%20disorder. [PubMed]
  • 48.Castori M. Ehlers-danlos syndrome, hypermobility type: an underdiagnosed hereditary connective tissue disorder with mucocutaneous, articular, and systemic manifestations. International Scholarly Research Notices. 2012;2012. doi: 10.5402/2012/751768 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Malfait F, Francomano C, Byers P, Belmont J, Berglund B, Black J, et al. The 2017 international classification of the Ehlers–Danlos syndromes. InAmerican Journal of Medical Genetics Part C: Seminars in Medical Genetics 2017. Mar (Vol. 175, No. 1, pp. 8–26). doi: 10.1002/ajmg.c.31552 [DOI] [PubMed] [Google Scholar]
  • 50.Ehlers Danlos Support UK. The Ehlers-Danlos syndromes (EDS) GP Toolkit. https://gptoolkit.ehlers-danlos.org/ Last accessed 26/02/2024.
  • 51.Malfait F, Wenstrup RJ, De Paepe A. Clinical and genetic aspects of Ehlers-Danlos syndrome, classic type. Genetics in medicine. 2010. Oct 1;12(10):597–605. doi: 10.1097/GIM.0b013e3181eed412 [DOI] [PubMed] [Google Scholar]
  • 52.Callewaert B., Malfait F., Loeys B., De Paepe A. 2008. Ehlers-Danlos syndromes and Marfan syndrome. Best Practice and Research: Clinical Rheumatology, Mar;22(1):165–89. https://www.sciencedirect.com/science/article/abs/pii/S1521694207001386?via%3Dihub. doi: 10.1016/j.berh.2007.12.005 [DOI] [PubMed] [Google Scholar]
  • 53.Fibromyalgia Australia. 2023. Medicare, Centrelink and NDIS. https://fibromyalgiaaustralia.org.au/practitioners/medicare-centrelink-ndis/ Last accessed 18/01/2024.
  • 54.Levy, H.P. 2016. Ehlers-Danlos Syndrome, Hypermobility Type. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews [Internet] Seattle, WA: University of Washington, Seattle; 1993–2016. Updated March 31, 2016. Hypermobile Ehlers-Danlos Syndrome—GeneReviews®—NCBI Bookshelf (nih.gov).
  • 55.Berglund B, Nordström G, Lützén K. Living a restricted life with Ehlers-Danlos syndrome (EDS). International Journal of Nursing Studies. 2000. Apr 1;37(2):111–8. Available at: Living a restricted life with Ehlers-Danlos Syndrome (EDS)—ScienceDirect. doi: 10.1016/s0020-7489(99)00067-x [DOI] [PubMed] [Google Scholar]
  • 56.Halverson CM, Penwell HL, Francomano CA. Clinician-associated traumatization from difficult medical encounters: Results from a qualitative interview study on the Ehlers-Danlos Syndromes. SSM-Qualitative Research in Health. 2023. Jun 1;3:100237. doi: 10.1016/j.ssmqr.2023.100237 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Langhinrichsen-Rohling J, Lewis CL, McCabe S, Lathan EC, Agnew GA, Selwyn CN, et al. They’ve been BITTEN: reports of institutional and provider betrayal and links with Ehlers-Danlos Syndrome patients’ current symptoms, unmet needs and healthcare expectations. Therapeutic Advances in Rare Disease. 2021. Jun;2:26330040211022033. doi: 10.1177/26330040211022033 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Bennett SE, Walsh N, Moss T, Palmer S. The lived experience of Joint Hypermobility and Ehlers-Danlos Syndromes: a systematic review and thematic synthesis. Physical Therapy Reviews. 2019. Mar 4;24(1–2):12–28. [Google Scholar]
  • 59.Halverson CM, Kroenke K, Penwell HL, Francomano CA. Evolving attitudes toward numeric pain assessment among patients with hypermobile Ehlers-Danlos syndrome: A qualitative interview study. Pain Medicine. 2023. Jun 1;24(6):713–5. Available at: https://pubmed.ncbi.nlm.nih.gov/36322007/. doi: 10.1093/pm/pnac167 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Huynh H.P. and Dicke-Bohmann A. 2020. Humble doctors, healthy patients? Exploring the relationships between clinician humility and patient satisfaction, trust, and health status. Patient Education and Counseling, Jan; 103(1): 173–179. Available at: https://pubmed.ncbi.nlm.nih.gov/31416683/. doi: 10.1016/j.pec.2019.07.022 [DOI] [PubMed] [Google Scholar]
  • 61.Ruberton PM, Huynh HP, Miller TA, Kruse E, Chancellor J, Lyubomirsky S. The relationship between physician humility, physician–patient communication, and patient health. Patient education and counseling. 2016. Jul 1;99(7):1138–45. Available at: https://pubmed.ncbi.nlm.nih.gov/26830544/. doi: 10.1016/j.pec.2016.01.012 [DOI] [PubMed] [Google Scholar]
  • 62.Bradshaw J., Siddiqui N., Greenfield D., Sharma A. 2022. Kindness, Listening, and Connection: Patient and Clinician Key Requirements for Emotional Support in Chronic and Complex Care. Journal of Patient Experience, Apr 12;9. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008851/. doi: 10.1177/23743735221092627 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Rombaut L, Deane J, Simmonds J, De Wandele I, De Paepe A, Malfait F, et al. Knowledge, assessment, and management of adults with joint hypermobility syndrome/Ehlers–Danlos syndrome hypermobility type among Flemish physiotherapists. In American Journal of Medical Genetics Part C: Seminars in Medical Genetics 2015. Mar (Vol. 169, No. 1, pp. 76–83). doi: 10.1002/ajmg.c.31434 [DOI] [PubMed] [Google Scholar]
  • 64.Greenacre ZA. The importance of selection bias in internet surveys. Open Journal of Statistics. 2016. Jun 8;6(3):397–404. [Google Scholar]
  • 65.Jager J, Putnick DL, Bornstein MH. More than just convenient: The scientific merits of homogeneous convenience samples. Monographs of the Society for Research in Child Development. 2017. Jun;82(2):13–30. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.O’Connor S. Designing and using surveys in nursing research: a contemporary discussion. Clinical Nursing Research. 2022. May;31(4):567–70. doi: 10.1177/10547738211064739 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Althubaiti A. Information bias in health research: definition, pitfalls, and adjustment methods. Journal of multidisciplinary healthcare. 2016. May 4:211–7. doi: 10.2147/JMDH.S104807 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Martin E Matsumura

12 Jun 2024

PONE-D-24-18819An exploration of the journey to diagnosis of Ehlers-Danlos Syndrome (EDS) for women living in AustraliaPLOS ONE

Dear Dr. Flood,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jul 27 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Martin E. Matsumura, MD

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please include a complete copy of PLOS’ questionnaire on inclusivity in global research in your revised manuscript. Our policy for research in this area aims to improve transparency in the reporting of research performed outside of researchers’ own country or community. The policy applies to researchers who have travelled to a different country to conduct research, research with Indigenous populations or their lands, and research on cultural artefacts. The questionnaire can also be requested at the journal’s discretion for any other submissions, even if these conditions are not met.  Please find more information on the policy and a link to download a blank copy of the questionnaire here: https://journals.plos.org/plosone/s/best-practices-in-research-reporting. Please upload a completed version of your questionnaire as Supporting Information when you resubmit your manuscript.

3. For studies involving third-party data, we encourage authors to share any data specific to their analyses that they can legally distribute. PLOS recognizes, however, that authors may be using third-party data they do not have the rights to share. When third-party data cannot be publicly shared, authors must provide all information necessary for interested researchers to apply to gain access to the data. (https://journals.plos.org/plosone/s/data-availability#loc-acceptable-data-access-restrictions

For any third-party data that the authors cannot legally distribute, they should include the following information in their Data Availability Statement upon submission:

1) A description of the data set and the third-party source

2) If applicable, verification of permission to use the data set

3) Confirmation of whether the authors received any special privileges in accessing the data that other researchers would not have

4) All necessary contact information others would need to apply to gain access to the data

4. Please include your full ethics statement in the ‘Methods’ section of your manuscript file. In your statement, please include the full name of the IRB or ethics committee who approved or waived your study, as well as whether or not you obtained informed written or verbal consent. If consent was waived for your study, please include this information in your statement as well. 

5. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. 

Additional Editor Comments 

Please address all feedback below.

Please note that 1 reviewer feedback is on an attached document which can be accessed below

Editor note: I feel that the inclusion of variables with "zero" respondents (comment regarding table 2) can be left in the tables as these reflect the questions asked in the survey.  

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: N/A

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: I have several minor issues to address on revision. Details are provided in attached document. Primary issues are related to table formatting and use of the term "misdiagnosis" to designate earlier diagnoses.

Reviewer #2: A detailed review of the manuscript titled: “An exploration of the journey to diagnosis of Ehlers-Danlos Syndrome (EDS) for women living in Australia.”

There are several critical issues that require attention for the study to achieve its intended impact. The authors should revise the manuscript and address these major critics. Below are my comments and suggestions:

1-Authors grouped all Ehlers-Danlos syndrome (EDS) subtypes together, and provided a prevalence. The method used estimated the prevalence of EDS globally and applies it to the Australian population. Their statistical assessment based on a presumed and inaccurate prevalence, considering the variable and largely unknown prevalence of individual EDS subtypes.

The study specifically addresses the prevalence and clinical characteristics of hypermobile Ehlers-Danlos Syndrome (hEDS). Given the distinct nature and higher prevalence of hEDS compared to other EDS subtypes, it is imperative to focus exclusively on hEDS to provide accurate and clinically relevant data.

2- The convenience sampling method used in the study is prone to biases that cannot be generalized beyond the specific sample studied. The authors should present their data as an exploratory or pilot study, generating hypotheses for more rigorous research designs using probability sampling methods. This approach would prevent the overstatement of findings and acknowledge the limitations inherent to convenience sampling.

3- The authors should explicitly include self-selection bias, inaccurate or false data, and recall bias as limitations of the study. Recognizing these biases will provide a more balanced interpretation of the study’s findings.

4- Several statements in the article represent inaccurate information about hEDS, including:

o “EDS alters collagen structures in the body leading to multi-systemic complications including generalized joint hypermobility,…” and “functional decline is common place.” The etiology of hEDS is unknown, and it is generally not caused by defective collagen. The condition is not progressive.

o “Several reports indicate that over 70% of EDS cases occur in women with over 90% of hEDS cases being female.” While hEDS is more common in females, there is no sex predominance in other EDS subtypes.

o “Due to the ‘invisible’ nature of EDS, patient reports of their symptoms, particularly before they are accurately diagnosed with EDS, are often dismissed.” The term "invisible" is not appropriate; the authors likely refer to the lack of a pathognomonic biomarker. Additionally, this statement refer specifically to hEDS and should be clarified.

5-The initial questionnaire design was based on an extensive literature search and the lead researcher’s anecdotal experience as an occupational therapist. While practical insights are valuable, the lead researcher’s expertise is in managing EDS complications rather than diagnosing it. Including an expert in EDS diagnosis, such as a geneticist or rheumatologist, would’ve ensured the questionnaire's accuracy and relevance. The authors should detail the specific expertise of the second researcher, clearly outlining their qualifications and experience in relation to EDS.

6- Revision of all these statements are required:

“The majority of participants (n=129; 84.9%) were misdiagnosed before being correctly diagnosed with EDS. Most participants were diagnosed with anxiety and/or depression (n=91; 73.4%) or another psychological condition (n=47; 37.9%), chronic pain (n=67; 54%), myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) (n=58; 46.8%), or another physical condition including fibromyalgia (n=18; 17.7%). Over 10% of respondents (n=14) received more than nine misdiagnoses before being correctly diagnosed with EDS.”

“Most participants were misdiagnosed prior to receiving their formal diagnosis of EDS with over ten percent of respondents receiving more than nine misdiagnoses.”

“Participants consistently reported being referred to numerous specialists who lack knowledge regarding EDS, often resulting in misdiagnosis.”

“While misdiagnosis is expected and consistent with previous findings the extent of misdiagnosis reported in this study is astonishing.”

These statements are stemmed from a question that does not specify the timeframe, context, or criteria for what constitutes a "misdiagnosis (questions 11, and 16. This lack of clarity can lead to inconsistent interpretations and responses from participants. Without rigorous validation and a clear, objective framework for assessing misdiagnoses, self-reported data on this topic are likely to be inaccurate and unreliable, making all the conclusions unreliable.

Patients' perceptions of being misdiagnosed, and their understanding of what diagnostic tool has been used, can be highly subjective and influenced by their understanding of their symptoms and conditions. The question does not include a mechanism for verifying the reported misdiagnoses against medical records or clinical evaluations. Without validation from healthcare professionals, it is impossible to determine if the reported misdiagnoses are accurate.

Conditions such as Chronic Fatigue Syndrome (CFS), Myalgic Encephalomyelitis (ME), and fibromyalgia have evolving diagnostic criteria, which can vary between practitioners and over time. In addition, patients who feel dissatisfied with their care or outcomes may be more likely to report being misdiagnosed, introducing a potential bias in the survey responses.

7-The statement, "As FM alone is not formally recognized by the National Disability Insurance Agency in Australia (NDIA) or Centrelink (Australian welfare system), there is much debate about how helpful a diagnosis of FM is and whether FM is diagnosed in the absence of an alternative clear diagnosis," requires revision for several reasons:

Fibromyalgia (FM) is recognized globally and has been assigned an ICD code (International Classification of Diseases) long before hypermobile Ehlers-Danlos Syndrome (hEDS). The ICD-10 code for FM is M79.7, and it has been widely used in medical diagnosis and research. This recognition reflects the consensus within the medical community about FM as a legitimate and distinct medical condition.

The American College of Rheumatology has established specific diagnostic criteria that healthcare providers use to diagnose FM based on clinical findings. The lack of formal recognition by specific national agencies, such as the NDIA or Centrelink, does not diminish the validity of the diagnosis itself. It is important to distinguish between administrative recognition for the purposes of disability support and the medical validity of the diagnosis. The statement conflates these two distinct issues, potentially misleading readers about the legitimacy of FM as a clinical diagnosis.

In addition FM can co-occur with other conditions. Misrepresenting the status of FM can contribute to stigma and misunderstanding, which can negatively impact patients seeking support and treatment.

Therefore, it is recommended that the statement be revised to reflect the established medical recognition of fibromyalgia and clarify the distinction between administrative recognition for disability support and medical diagnosis. An accurate portrayal will ensure the article is informative and respectful of the condition's legitimacy.

8- The statement, "While Physiotherapists made only 6.6% of the EDS diagnoses of participants in this study, this group of allied health professionals are aptly positioned to diagnose and treat EDS in conjunction with referrals to other appropriate specialists," requires clarification.

While physiotherapists play a crucial role in the multidisciplinary care of patients with hypermobile Ehlers-Danlos Syndrome (hEDS), their primary expertise lies in the management and rehabilitation of musculoskeletal issues, rather than in the diagnosis of complex genetic conditions. According to the 2017 International Classification of the Ehlers-Danlos Syndromes, the diagnosis of hEDS includes the exclusion of alternative diagnoses, which involves a comprehensive clinical assessment that includes detailed patient history, physical examination, and the exclusion of other conditions with overlapping phenotypes. This process typically requires the expertise of a medical professional trained in genetics, rheumatology, or another relevant specialty. Physiotherapists do not possess the necessary training or authority to perform the required comprehensive diagnostic workup.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: Reviewer response PONE-D-24-18819.docx

pone.0307574.s002.docx (19.5KB, docx)

Decision Letter 1

Martin E Matsumura

9 Jul 2024

An exploration of the journey to diagnosis of Ehlers-Danlos Syndrome (EDS) for women living in Australia

PONE-D-24-18819R1

Dear Dr. Flood,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Martin E. Matsumura, MD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Thank you for addressing all reviewer comments. My only additional comment- the statements you added to tables 11 and 12 to indicate patients could pick multiple answers- please change "chose" to "choose"

Acceptance letter

Martin E Matsumura

17 Jul 2024

PONE-D-24-18819R1

PLOS ONE

Dear Dr. Flood,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Martin E. Matsumura

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Appendix. Participant survey.

    (DOCX)

    pone.0307574.s001.docx (17.7KB, docx)
    Attachment

    Submitted filename: Reviewer response PONE-D-24-18819.docx

    pone.0307574.s002.docx (19.5KB, docx)
    Attachment

    Submitted filename: Response table.docx

    pone.0307574.s003.docx (24.8KB, docx)

    Data Availability Statement

    Access to the full data can be obtained by request to the Nursing and Health Research Ethics Filter Committee in Ulster University (contact wg.kernohan@ulster.ac.uk).


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES